The 12th International Lung Cancer Congress will provide physicians with practical information regarding the clinical implications of lung cancer screening, the latest clinical data impacting the treatment of lung cancer, and novel agents and strategies that are changing the future of lung cancer therapy. The importance of personalized therapy will be emphasized, followed by other current topics of interest. State-of-the-art treatment for non–small-cell lung cancer (NSCLC) by stage, SCLC, and mesothelioma will be discussed. Didactic lectures and debates will be used to reinforce current standards and to present emerging clinical data. Faculty will be encouraged to discuss practice-changing data in a case-based framework that will provide physicians with the necessary context to integrate the information into their practice to improve treatment selection and patient care. This educational program will provide medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, and oncology professionals with practical information regarding the clinical implications of lung cancer screening, the latest clinical data impacting the treatment of lung cancer, and novel agents and strategies that are changing the future of lung cancer therapy.